Core Insights - Peijia Medical-B (9996.HK) experienced a stock price increase of 8.26% to HKD 6.29, reaching a nearly two-month high since October 21 [1] - The company announced the approval of its TaurusTrio™ Transcatheter Aortic Valve (TAV) system by the National Medical Products Administration of China, with expectations for a successful market launch in China by December 11, 2025 [1] - The TaurusTrio™ TAV system aims to provide a safe and effective treatment option for Chinese patients suffering from severe aortic regurgitation (AR), addressing a significant unmet clinical need [1] - CEO and Chairman Zhang Yi has begun purchasing company shares in the open market since December 1, 2025, with a total investment not exceeding HKD 15 million, reflecting confidence in the company's intrinsic value and growth potential [1] Company Developments - The approval of the TaurusTrio™ TAV system is a significant milestone for Peijia Medical, as it seeks to fulfill a critical demand in the Chinese healthcare market [1] - Zhang Yi's share purchase indicates a strong belief in the company's future prospects and may signal potential further investments in the company [1]

格隆汇12月12日丨拨康视云-B(02592.HK)发布公告，2025年12月10日，公司全资附属公司Cloudbreak USA与美国食品及药物管理局成功举行第2期临床试验后会议("第2期临床试验后会议")，该会议涉及 CBT-004的临床开发，而CBT-004为一种潜在的同类首创无防腐剂滴眼液，适用于治疗血管化睑裂斑， 该病症常见于紫外线照射过度者及年长者。 第2期临床试验后会议乃基于2025年5月完成的第2期临床试验结果及2025年7月完成的临床试验报告而举 行，该报告显示CBT-004在受试者中具有安全性且耐受性良好，并达到主要疗效终点及若干次要疗效终 点。尤其是，第2期临床试验结果显示CBT-004在减轻结膜充血方面具疗效，首次用药后最快7天即可见 效。于28天治疗期间，亦观察到包括灼热或刺痛感、搔痒及异物感等症状获得改善，部分症状改善效果 在停药后4周仍维持显著。治疗期间出现的不良事件均属轻微且暂时性，并无被视为与研究药物相关。 公司认为，成功举行第2期临床试验后会议标志着CBT-004临床开发取得重大进展，尤其是推动其进入 第3期临床研究，为CBT-004新药申请及获批后的商业化铺平道路。公司将 ...

格隆汇12月12日丨中航科工(02357.HK)发布公告，于临时股东会上，委任高继明为非执行董事已获股东 正式批准，有关委任随即生效。 ...

智通财经APP讯，吉利汽车(00175)发布公告，于2025年12月12日，该公司斥资2392.41万港元回购136.2 万股。 ...

拨康视云-B(02592)公布，于2025年12月10日，公司全资附属公司Cloudbreak USA与美国食品及药物管 理局成功举行第2期临床试验后会议，该会议涉及CBT-004的临床开发，而CBT-004为一种潜在的同类首 创无防腐剂滴眼液，适用于治疗血管化睑裂斑，该病症常见于紫外线照射过度者及年长者。 于第2期临床试验后会议上，美国食品及药物管理局就下列事项提供意见回馈：药物稳定性及规格研 究、支持向美国食品及药物管理局提交拟议新药申请所需的非临床研究，以及CBT-004第3期临床研究 的设计及终点。其中，美国食品及药物管理局与Cloudbreak USA就以下事项达成共识：将充血症状减轻 作为CBT-004获批的主要终点，其统计学及临床意义，并将症状缓解作为潜在的共同主要终点。 第2期临床试验后会议乃基于2025年5月完成的第2期临床试验结果及2025年7月完成的临床试验报告而举 行，该报告显示CBT-004在受试者中具有安全性且耐受性良好，并达到主要疗效终点及若干次要疗效终 点。尤其是，第2期临床试验结果显示CBT-004在减轻结膜充血方面具疗效，首次用药后最快7天即可见 效。于28天治疗期间，亦观 ...

Group 1 - The company, China Gas Holdings Limited (stock code: 08246), announced the issuance of 140 million capitalization shares based on a loan capitalization agreement established on October 20, 2025, which received special authorization from independent shareholders at a special general meeting on December 8, 2025 [1]

Core Viewpoint - The stock price of Kangfang Biotech (09926) is currently at 121 HKD, reflecting a 3.6% increase, with significant market activity and divergent views among investors [1][5]. Market Performance - Over the past five days, the stock has shown a volatility of 11.9%, with a trading volume of 236 million HKD, indicating active trading [1]. - Other stocks in the same sector have varied performances, with BeiGene (06160.HK) up 0.95% at 191.5 HKD, Innovent Biologics (01801.HK) up 0.24% at 83.75 HKD, and others showing declines [1]. Technical Analysis - The current stock price is slightly below the 10-day moving average (121.5 HKD) but above the 30-day moving average (116.85 HKD), indicating short-term pressure while the mid-term structure remains intact [2]. - Key support levels are identified at 111.7 HKD (Support 1) and 103.3 HKD (Support 2), with resistance levels at 123 HKD (Resistance 1) and 130.3 HKD (Resistance 2) [2]. - The overall probability of an upward movement is estimated at 56%, suggesting a slightly positive outlook [2]. Fundamental Catalysts - A significant recent development is the inclusion of all five self-developed drugs by Kangfang Biotech in the latest National Medical Insurance catalog, effective January 1, 2026 [5]. - This inclusion is viewed as a critical step towards accelerating the commercialization of innovative drugs, with expectations of rapid sales growth following the listing [5]. Investor Sentiment - Investor opinions are divided into three main perspectives: 1. Optimistic view anticipating significant stock price increases due to potential market expansion from medical insurance [5]. 2. Cautious view considering previous price volatility, leading some investors to take profits at current levels [5]. 3. Pessimistic view predicting a potential price correction to around 110 HKD for consolidation [5]. Derivative Products - In a volatile market, the leverage characteristics of derivative products are highlighted, with examples showing significant price movements in response to stock fluctuations [6][7]. - For bullish investors, options such as Huatai call warrants (22043) with a strike price of 138 HKD and a leverage of 2.7 times are recommended [9]. - For bearish investors, Huatai put warrants (29749) with a strike price of 95 HKD and a leverage of 1.2 times are suggested for hedging against potential declines [16].

新京报贝壳财经讯 12月12日，据首形科技微信公众号消息，首形科技宣布完成新一轮融资。本轮由中 国互联网投资基金（中网投）与蚂蚁集团联合领投，其他投资人包括上海未来产业基金、东方富海，老 股东招商局创投持续超额追投，深蓝资本担任独家财务顾问。本轮融资将主要用于产品矩阵扩展、小批 量量产体系搭建，以及核心模型与软件算法的持续迭代。这也是首形科技今年完成的第四轮融资。 ...

中航科工(02357)发布公告，于2025年12月12日，公司董事会审议并批准建议实施公司股东国家军民融 合产业投资基金有限责任公司所持有的公司2.62亿股内资股股份(占本公告日期本公司已发行股份总数 约3.28%)转换为公司H股。 ...

本公司亦宣布，自2025年12月12日起，非执行董事顾虹博士获委任为审计委员会成员，非执行董事李钧 博士不再担任审计委员会成员。为将更多时间投入其他业务和个人事务，李钧博士不再担任审计委员会 成员。 江先生自2025年12月12日起获委任后，随即获委任为审计委员会主席以及薪酬委员会成员及提名委员会 成员。 同源康医药-B(02410)发布公告，江晓林先生(江先生)已获委任为独立非执行董事、董事会审计委员会 (审计委员会)主席、董事会薪酬与考核委员会(薪酬委员会)成员及提名委员会(提名委员会)成员，自2025 年12月12日起生效。 ...